Staphylococcus

Although many gene-inactivation technologies have been applied to bacterial genetics, the potential for using antisense technology has not been extensively explored. In the September 21 Science, Yindo Ji and colleagues from GlaxoSmithKline Pharmaceuticals in Collegeville, Pennsylvania, describe a comprehensive genomic analysis of the human pathogen Staphylococcus aureus using a regulated antisense strategy (Science 2001, 293:2266-2269).They used an adapted tetracycline-dependent (tet) regulatory

Jonathan Weitzman(jonathanweitzman@hotmail.com)
Sep 20, 2001

Although many gene-inactivation technologies have been applied to bacterial genetics, the potential for using antisense technology has not been extensively explored. In the September 21 Science, Yindo Ji and colleagues from GlaxoSmithKline Pharmaceuticals in Collegeville, Pennsylvania, describe a comprehensive genomic analysis of the human pathogen Staphylococcus aureus using a regulated antisense strategy (Science 2001, 293:2266-2269).

They used an adapted tetracycline-dependent (tet) regulatory system to drive the expression of small fragments of sheared DNA. Colonies were selected that grew in the absence of anhydrotetracycline but not when expression was induced. About 3% of colonies were growth-defective or lethal upon induction, and about a third of these contained single-ORF antisense constructs. This method allows easy isolation and maintenance of conditional growth-defective strains, and rapid identification of the relevant gene.

Ji et al. identified over 150 genes that are critical for growth and survival, and are potential targets for...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?